Predicting response to a HER inhibitor
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jul 19, 2011
Grant Date -
Jan 14, 2010
app pub date -
Mar 1, 2008
filing date -
Mar 2, 2007
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab.It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab.In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully